Calidi Biotherapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Calidi Biotherapeutics, Inc. (CLDI) reported Gain (Loss) on Extinguishment of Debt of -$471.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-11-14
- 2023-09-30: Gain (Loss) on Extinguishment of Debt 9 month -$471.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 9 month |
|---|---|
| 2023-09-30 | -$471.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |